Researchers Note Lack of Benefit with AI in Women with Dense Breasts
In a study of over 1.300 women with dense breasts, the combination of mammography and ultrasound had a recall rate of 11.7 percent, a specificity rate of 89.1 percent and an accuracy rate of 89.2 percent in comparison to a 21.4 percent recall rate, 79.4 percent specificity and 79.5 percent accuracy for the combination of mammography, ultrasound, and artificial intelligence (AI).
UltraSight's AI-Powered Cardiac Ultrasound Guidance Gets FDA Nod
Indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) in adults, the AI Guidance software reportedly enables novice ultrasound users to obtain real-time cardiac imaging at the point of care.
Can Low-Dose CT Have an Impact in Diagnosing Bone Metastasis in Patients with Prostate Cancer?
In a study of 601 patients with prostate cancer, researchers found that only one patient with extensive metastasis was falsely diagnosed as non-metastatic on whole-body, low-dose computed tomography (CT) by reviewing radiologists.
Mammography-Based Deep Learning Model May Help Detect Precancerous Changes in High-Risk Women
In a dataset enriched for African American women, BRCA mutation carriers and those with benign breast disease, a mammography-based deep learning model demonstrated a five-year AUC of 63 percent for predicting breast cancer in comparison to 54 percent for BI-RADS assessment.
Study: AI Assessment of Chest CT May Predict Multiple Mortality Risks
In a study of over 20,700 people, researchers found that artificial intelligence (AI) analysis of body composition measurements via lung cancer screening computed tomography (CT) exams improves the prediction of mortality risks for lung cancer, cardiovascular disease, and all-cause mortality.
Stabilizing Medicare Reimbursement: A Plan For Action
July 25th 2023Noting that the Medicare conversion factor in 2024 could be lower than the rate in 1993, this author discusses three key issues that need to be addressed by government leaders in order to ensure equitable Medicare reimbursement for radiologists and other physicians.
Meta-Analysis Compares MRI-Guided SBRT and CT-Guided SBRT for Prostate Cancer
A newly published review of 29 prospective studies revealed the use of MRI-guided daily adaptive SBRT in the management of prostate cancer was associated with significantly lower risks of acute grade 2 or higher genitourinary (GU) and gastrointestinal (GI) toxicities in comparison to CT-guided non-adaptive SBRT.
Ultrasound-Derived Fibroid Mapping Technology Gets FDA Nod
The newly FDA-cleared Fibroid Mapping Reviewer Application, which allows the creation of 3D uterus models from ultrasound images, reportedly facilitates diagnosis and interventional procedures for patients with uterine fibroids.
How Socioeconomic Disparities Affect Follow-Up of Incidental Pulmonary Nodules on CT
In a study of nearly 2,500 patients with incidental pulmonary nodules (IPN) on chest computed tomography (CT) exams, 69.5 percent of those in the highest quartile of the CDC’s Social Vulnerability Index (SVI) had inappropriate IPN follow-up in comparison to 54.3 percent of those in the lowest quartile of the CDC SVI.
Emerging Perspectives on Amyloid PET Imaging for Alzheimer's Disease
In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
MRI Study: Half-Dose Gadopiclenol Offers Similar Visualization and Safety as Full-Dose Gadobutrol
Newly published research suggests the use of gadopiclenol at 0.05 mmol/kg is non-inferior to gadobutrol 0.1 mmol/kg for all qualitative visualization parameters on full-body magnetic resonance imaging (MRI).
Can AI Bolster MRI Lesion Detection and Segmentation in Patients with Multiple Sclerosis?
An artificial intelligence model, trained on MRI and FLAIR imaging from over 900 patients with multiple sclerosis, demonstrated a 96 percent accuracy rate and 99 percent specificity rate for contrast-enhancing lesions in this patient population.
CMS Proposes Lift of Coverage Restrictions on PET Imaging for Alzheimer's Disease
Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PET scan per lifetime.